PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 11, 2018ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)456 citationsOpen Access

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure

KDKevin DammanMGMauro GoriBCBrian Claggett

Structured PICO

Does sacubitril/valsartan reduce the rate of eGFR decrease and improve cardiovascular outcomes compared to enalapril in patients with heart failure?

P
Population
Patients with heart failure, including those with chronic kidney disease
I
Intervention
Sacubitril/valsartan
C
Comparator
Enalapril
O
Outcome
Rate of decrease in eGFR and cardiovascular outcomes

Sacubitril/valsartan provides renoprotective effects by slowing eGFR decline while improving cardiovascular outcomes in heart failure patients compared to enalapril.

Abstract

Compared with enalapril, sacubitril/valsartan led to a slower rate of decrease in the eGFR and improved cardiovascular outcomes, even in patients with chronic kidney disease, despite causing a modest increase in UACR.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Damman et al. (2018) studied this question.

synapsesocial.com/papers/69d5724975589c71d767e6bchttps://doi.org/10.1016/j.jchf.2018.02.004
Ask AI
Helpful
Bookmark
Share
View Full Paper